July 15, 2019

Corporate Relationship Department Manager – Listing

M/s. BSE Ltd M/s. National Stock Exchange of India Ltd
Dalal Street, Fort “Exchange Plaza”, Bandra – Kurla Complex
Mumbai- 400 001 Bandra (E) Mumbai -400 051

Scrip Code: 524816 Scrip Code: NATCOPHARM

Dear Sir

Please find enclosed the Press Release for your information.

Thanking you

Yours faithfully
For NATCO Pharma Limited

M Adinarayana
Company Secretary &
Vice President (Legal & Corp Affairs)
Ref: PR/ 7 /2019-2020 Press Release

NATCO COMPLETES USFDA INSPECTION

FOR CHENNAI API FACILITY WITH ZERO OBSERVATIONS

Hyderabad, India, July 15th, 2019

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) is pleased to announce

successful completion of regulatory inspection from the U.S. Food and Drug
Administration (FDA) for its Active Pharmaceutical Ingredient (API) facility in
Chennai, India, conducted during the period July 8th – 12th, 2019. The regulatory
audit resulted in zero observations.
________________________________________________________________
Forwarded for favour of publication
For NATCO Pharma Limited

M Adinarayana
Company Secretary &
Vice President (Legal & Corp Affairs)